Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InterMune
Brisbane, California, United States
- Ownership
- Private
- Employees
- ~450
- Development stage
- Other
01
Overview
InterMune developed pirfenidone (Esbriet), a treatment for idiopathic pulmonary fibrosis. The drug received FDA approval in October 2014 after initially being rejected in 2010 and requiring additional Phase III trials. It was previously approved in Canada (2011) and Europe (2012).
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Partnerships
Roche (2006-2010 collaboration before acquisition)
Beyond the preview
Go deeper on InterMune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InterMune.